Track topics on Twitter Track topics that are important to you
P.O. Box 303
Phone: 46 (0)18 780 88 00
Fax: 46 (0)18 780 88 88
Orexo and MundiPharma were granted marketing authorization by the European Medicines Agency for Zubsolv, or buprenorphine and -More-
Edison Investment Research - Pharmaceutical & healthcare - Orexo: Orexo’s Q3 highlighted a strong financial quarter. Zubsolv US revenue declines of 15% vs Q316 (Q316 benefited from significant o...
Nasdaq Stockholm decides to officially list 1 bond loan issued by Orexo AB with effect from 2017-12-01. The instrument will be listed on STO Corporate Bonds. Please find instrument identifiers in t...
Orexo är redo att lansera substitutionsbehandlingen utanför USA.
The European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence.
NewsZubsolv is a sublingual tablet licensed for people with opioid dependence within a framework of medical, social, and psychological treatment. It is the first such therapy to be approved in a choic...
Entering 2018, Zubsolv will have stronger market access position than ever in the US. In the commercial segment Zubsolv's formulary access as from January 1, Read more...
This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge mod...
We start by matching unmet patient needs with the unrealized potential in many existing compounds. We create novel pharmaceuticals, at lower development cost and risk, with shorter time to market. The...
We have published hundreds of Orexo AB news stories on BioPortfolio along with dozens of Orexo AB Clinical Trials and PubMed Articles about Orexo AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Orexo AB Companies in our database. You can also find out about relevant Orexo AB Drugs and Medications on this site too.